LY-178210, also known as LY-228729 or as 4,α-methylene-5-carboxamido-DPT, is a selective and highly potent serotonin 5-HT1A receptor partial agonist. It has an affinity (Ki) of 0.67 nM for the serotonin 5-HT1A receptor. The drug has high selectivity for this receptor over 12 other assessed targets, including the serotonin 5-HT1D, 5-HT2A, 5-HT2C, and 5-HT3 receptors among others (Ki = ≥380–4,000 nM). LY-178210 is a tricyclic simplified or partial ergoline and is structurally related to LSD. It was described as a potential clinical development candidate but was not further developed and was never marketed. Both LY-178210 and flesinoxan have been reported to produce anxiety in humans. The drug was first reported in the scientific literature by 1990.
See also Partial lysergamide LY-301317 RU-27849 RU-28306 Bay R 1531 (LY-197206) LY-293284 NDTDI 8-OH-DPAT Alentemol
References


